Tissue Diagnostics Market by Product (Consumables (Antibodies, Reagents, Tissue, Probes), Instrument (Processing System, Scanner)), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) - Global Forecast to 2028
The global tissue diagnostics market is projected to reach USD 8.4 billion by 2028 from USD 5.6 billion in 2023, at a CAGR of 8.4% during the forecast period. Market growth is driven by factors such as the rising prevalence of cancer, increasing availability of reimbursements and increasing technological advancements in tissue diagnostics are the major factors driving the growth of the market.
“The Consumables to register the largest share of the tissue diagnostics market, by product.”
The global tissue diagnostics market product segment is divided into Consumables and Instruments . In product segment the consumables is expected to account for the largest share of the tissue diagnostics market in 2022. Market growth is largely driven by the rise in government and private funding in life sciences and cancer research, growing R&D expenditure by leading pharma companies. Moreover, the availability of better consumables that offer efficient results and precision in diagnosis attributes to their growing demand, resulting in growth of the segment.
“Immunohistochemistry tissue diagnostics segment to grow at a considerable rate among technology during the forecast period.”
The tissue diagnostics market is four technology segments, namely, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology & Workflow, and Special Staining. The Immunohistochemistry technology segment is expected to account for the largest share of the tissue diagnostics market in 2022. The large share of this segment can primarily be attributed to the Rising geriatric population and growing prevalence of cancer diseases diabetes, availability of reimbursements for IHC tests, and adoption of digital pathology are driving the demand for immunohistochemistry products.
“Breast Cancer segment accounted for the largest share in the tissue diagnostics market, by disease.”
The global tissue diagnostics market is segmented into Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-small Cell Lung Cancer, and Other Diseases. The breast cancer segment accounted for a largest share in 2022, primarily due number of factors such as age, family history, reproductive history, the presence of dense breast tissues, a lack of physical activity, alcohol consumption, smoking, radiation exposure coupled with the increasing incidence of breast cancer such as ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and inflammatory breast cancer (IBC), among others.
“Asia Pacific: The fastest-growing region in the tissue diagnostics market.”
The global tissue diagnostics market is segmented into four major regions - North America, Europe, the Asia Pacific, and Rest of the World (RoW). The Asia Pacific region is expected to grow at the highest rate in the tissue diagnostics market during the forecast period. The high growth in the region is due to the presence of a large target population, the economic growth in the countries of this region and rising prevalence of cancer in Asian countries.
The break-up of the profile of primary participants in the tissue diagnostics market:
Research Coverage:
This research report categorizes the tissue diagnostics market by product (consumables and instruments), technology (immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology & workflow management, special staining), disease type (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, other disease types), end user (hospitals, research laboratories, pharmaceutical companies, Contract Research Organizations (CROs), and Other End Users), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the tissue diangostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the tissue diagnostics market. This report covers the competitive analysis of upcoming startups in the tissue diangostics market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall tissue diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
“The Consumables to register the largest share of the tissue diagnostics market, by product.”
The global tissue diagnostics market product segment is divided into Consumables and Instruments . In product segment the consumables is expected to account for the largest share of the tissue diagnostics market in 2022. Market growth is largely driven by the rise in government and private funding in life sciences and cancer research, growing R&D expenditure by leading pharma companies. Moreover, the availability of better consumables that offer efficient results and precision in diagnosis attributes to their growing demand, resulting in growth of the segment.
“Immunohistochemistry tissue diagnostics segment to grow at a considerable rate among technology during the forecast period.”
The tissue diagnostics market is four technology segments, namely, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology & Workflow, and Special Staining. The Immunohistochemistry technology segment is expected to account for the largest share of the tissue diagnostics market in 2022. The large share of this segment can primarily be attributed to the Rising geriatric population and growing prevalence of cancer diseases diabetes, availability of reimbursements for IHC tests, and adoption of digital pathology are driving the demand for immunohistochemistry products.
“Breast Cancer segment accounted for the largest share in the tissue diagnostics market, by disease.”
The global tissue diagnostics market is segmented into Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-small Cell Lung Cancer, and Other Diseases. The breast cancer segment accounted for a largest share in 2022, primarily due number of factors such as age, family history, reproductive history, the presence of dense breast tissues, a lack of physical activity, alcohol consumption, smoking, radiation exposure coupled with the increasing incidence of breast cancer such as ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and inflammatory breast cancer (IBC), among others.
“Asia Pacific: The fastest-growing region in the tissue diagnostics market.”
The global tissue diagnostics market is segmented into four major regions - North America, Europe, the Asia Pacific, and Rest of the World (RoW). The Asia Pacific region is expected to grow at the highest rate in the tissue diagnostics market during the forecast period. The high growth in the region is due to the presence of a large target population, the economic growth in the countries of this region and rising prevalence of cancer in Asian countries.
The break-up of the profile of primary participants in the tissue diagnostics market:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe – 21%, Asia Pacific – 18%, and Rest of the World- 10%
Research Coverage:
This research report categorizes the tissue diagnostics market by product (consumables and instruments), technology (immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology & workflow management, special staining), disease type (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, other disease types), end user (hospitals, research laboratories, pharmaceutical companies, Contract Research Organizations (CROs), and Other End Users), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the tissue diangostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the tissue diagnostics market. This report covers the competitive analysis of upcoming startups in the tissue diangostics market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall tissue diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (the rising prevalence of cancer, growing healthcare expenditure, growing demand for digital pathology, increasing healthcare expenditure, developing infrastructure for cancer diagnosis, increasing availability of reimbursements, and increasing technological advancements in tissue diagnostics are the major factors driving the growth of the market), restraints (high degree of consolidation, high cost of diagnostic imaging system), opportunities (significant opportunities in BRICS countries, growing demand for personalized medicines, increasing number of clinical trails perraining to cancer drugs, emerging economics to offer significant opportunities to companies), challenges (lack of skilled professionals, availability of refurbished products, stringent regulatory requirements, lack of infrastructure and low awareness in middle and low income countries and lack of standardization ) and trends (Increasing number of reagent rental agreements, increasing usage of Al in histopathology ) influencing the growth of the tissue diagnostics market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the tissue diagnostics market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the tissue diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tissue diagnostics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Agilent Technologies (US), Thermo Fisher Scientific Inc. (US), and among others in the tissue diagnostics market strategies.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS COVERED
FIGURE 1 MARKET SEGMENTATION
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 5 REVENUE SHARE ANALYSIS
FIGURE 6 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
FIGURE 7 TISSUE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.5.1 MARKET ASSUMPTIONS
2.5.2 GROWTH RATE ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT ANALYSIS
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 9 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
FIGURE 10 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
FIGURE 11 TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD BILLION)
FIGURE 12 TISSUE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF TISSUE DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 TISSUE DIAGNOSTICS MARKET OVERVIEW
FIGURE 14 RISING INCIDENCE OF CANCER AND INFECTIOUS DISEASES TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
4.2 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2022)
FIGURE 15 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 TISSUE DIAGNOSTICS MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 16 CHINA & INDIA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 TISSUE DIAGNOSTICS MARKET: REGIONAL MIX
FIGURE 17 ASIA PACIFIC REGION IS PROJECTED TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
4.5 TISSUE DIAGNOSTICS MARKET: DEVELOPED COUNTRIES VS. EMERGING ECONOMIES
FIGURE 18 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of cancer and infectious diseases
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2018 VS. 2020 VS. 2040
5.2.1.2 Growing demand for digital pathology
5.2.1.3 Increasing healthcare expenditure
FIGURE 20 CURRENT HEALTH EXPENDITURE PER CAPITA
FIGURE 21 CURRENT HEALTH EXPENDITURE (% OF GDP)
5.2.1.4 Growing availability of reimbursements
5.2.1.5 Rising establishment of private diagnostics centers
5.2.2 RESTRAINTS
5.2.2.1 High cost of tissue diagnostic systems
5.2.2.2 Stringent regulatory requirements
5.2.3 OPPORTUNITIES
5.2.3.1 High growth potential of emerging economies
FIGURE 22 GROWTH IN CURRENT HEALTHCARE EXPENDITURE IN BRICS COUNTRIES, 2012–2020
5.2.3.2 Growing preference for personalized medicines
FIGURE 23 PERSONALIZED MEDICINES APPROVED BY FDA (%), 2015–2022
5.2.3.3 Increasing number of clinical trials for cancer therapeutics
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled professionals
5.2.4.2 Availability of refurbished products
5.2.4.3 Inadequate standardization for TDx
5.2.5 INDUSTRY TRENDS
5.2.5.1 Increasing number of reagent rental agreements
5.2.5.2 Growing usage of AI in histopathology
5.3 VALUE CHAIN ANALYSIS
FIGURE 24 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 25 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.5 TECHNOLOGY ANALYSIS
5.6 PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 BARGAINING POWER OF BUYERS
5.6.3 BARGAINING POWER OF SUPPLIERS
5.6.4 THREAT OF SUBSTITUTES
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 KEY STAKEHOLDERS AND BUYING CRITERIA
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USERS
TABLE 4 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)
5.7.2 BUYING CRITERIA
FIGURE 27 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 5 KEY BUYING CRITERIA FOR END USERS
5.8 REGULATORY LANDSCAPE
TABLE 6 INDICATIVE LIST OF REGULATORY AUTHORITIES IN TISSUE DIAGNOSTICS MARKET
5.9 PATENT ANALYSIS
5.10 KEY CONFERENCES AND EVENTS
TABLE 7 LIST OF CONFERENCES & EVENTS (2023?2024)
5.11 PRICING ANALYSIS
TABLE 8 PRICE RANGE FOR TISSUE DIAGNOSTICS
5.12 TRADE ANALYSIS
TABLE 9 IMPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL/CHEMICAL ANALYSIS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 10 EXPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL/CHEMICAL ANALYSIS, BY COUNTRY, 2018–2022 (USD MILLION)
5.13 ECOSYSTEM MARKET/MAP
TABLE 11 TISSUE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
FIGURE 28 KEY PLAYERS OPERATING IN TISSUE DIAGNOSTICS MARKET
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6 TISSUE DIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 12 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 CONSUMABLES
TABLE 13 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 14 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2021–2028 (USD MILLION)
6.2.1 ANTIBODIES
6.2.1.1 Rising prevalence of infectious diseases to drive market
TABLE 15 TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
6.2.2 KITS
6.2.2.1 Optimized sensitivity and versatility to boost demand
TABLE 16 TISSUE DIAGNOSTICS MARKET FOR KITS, BY REGION, 2021–2028 (USD MILLION)
6.2.3 REAGENTS
6.2.3.1 Rising uptake in IHC and FISH procedures to support market growth
TABLE 17 TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2021–2028 (USD MILLION)
6.2.4 PROBES
6.2.4.1 Utilization in fluorescence microscopy applications to boost demand
TABLE 18 TISSUE DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS
TABLE 19 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 20 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
6.3.1 SLIDE-STAINING SYSTEMS
6.3.1.1 Development of high-throughput staining systems to drive market
TABLE 21 KEY MANUFACTURERS OF AUTOMATED SLIDE STAINERS
TABLE 22 TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2021–2028 (USD MILLION)
6.3.2 SCANNERS
6.3.2.1 Rising use of multiplexed IHC scanners to drive market
TABLE 23 TISSUE DIAGNOSTICS MARKET FOR SCANNERS, BY REGION, 2021–2028 (USD MILLION)
6.3.3 TISSUE-PROCESSING SYSTEMS
6.3.3.1 Rising need for automation to support market growth
TABLE 24 TISSUE DIAGNOSTICS MARKET FOR TISSUE-PROCESSING SYSTEMS, BY REGION, 2021–2028 (USD MILLION)
6.3.4 OTHER INSTRUMENTS
TABLE 25 TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
7 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 26 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 IMMUNOHISTOCHEMISTRY
7.2.1 RISING UPTAKE OF IHC KITS FOR DIAGNOSTIC APPLICATIONS TO FUEL MARKET
TABLE 27 TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2021–2028 (USD MILLION)
7.3 IN SITU HYBRIDIZATION
7.3.1 ABILITY TO DETECT SPECIFIC RNA AND DNA SEQUENCES TO BOOST DEMAND
TABLE 28 TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION)
7.4 DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT
7.4.1 RISING NEED FOR ANALYSIS AND SEAMLESS MANAGEMENT TO SUPPORT MARKET GROWTH
TABLE 29 TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT, BY REGION, 2021–2028 (USD MILLION)
7.5 SPECIAL STAINING
7.5.1 UTILIZATION IN CANCER DIAGNOSTICS TO BOOST DEMAND
TABLE 30 TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION, 2021–2028 (USD MILLION)
8 TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE
8.1 INTRODUCTION
TABLE 31 GLOBAL CANCER INCIDENCE, 2020 VS. 2040
TABLE 32 TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
8.2 BREAST CANCER
8.2.1 RISING UPTAKE OF HER2 TESTS FOR CANCER DIAGNOSIS TO DRIVE MARKET
TABLE 33 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
FIGURE 29 ARTICLES PUBLISHED ON BREAST CANCER TISSUE DIAGNOSTICS, 2011–2021
TABLE 34 TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION)
8.3 GASTRIC CANCER
8.3.1 RISING INCIDENCE OF GASTROINTESTINAL CANCER TO BOOST DEMAND
TABLE 35 COLON CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 36 TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2021–2028 (USD MILLION)
8.4 LYMPHOMA
8.4.1 RISING INCIDENCE OF NON-HODGKIN’S LYMPHOMA IN ADULTS TO SUPPORT MARKET GROWTH
TABLE 37 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 38 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 39 TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION, 2021–2028 (USD MILLION)
8.5 PROSTATE CANCER
8.5.1 RISING UPTAKE OF ISH TESTS FOR DIAGNOSIS TO FUEL MARKET
TABLE 40 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 41 TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION)
8.6 NON-SMALL CELL LUNG CANCER
8.6.1 GROWING FOCUS ON DEVELOPING COMPANION DIAGNOSTIC TESTS TO DRIVE MARKET
TABLE 42 TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2021–2028 (USD MILLION)
8.7 OTHER DISEASE TYPES
TABLE 43 TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASE TYPES, BY REGION, 2021–2028 (USD MILLION)
9 TISSUE DIAGNOSTICS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 44 TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 HOSPITALS
9.2.1 ABILITY TO OFFER ADVANCED EQUIPMENT & INFRASTRUCTURE TO DRIVE MARKET
TABLE 45 TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
9.3 RESEARCH LABORATORIES
9.3.1 RISING DEMAND OF SPECIALTY TESTS TO DRIVE MARKET
TABLE 46 TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
9.4 PHARMACEUTICAL COMPANIES
9.4.1 INCREASING R&D ACTIVITIES FOR DISEASE DIAGNOSTICS TO DRIVE MARKET
TABLE 47 TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 OUTSOURCING OF R&D ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 48 CONTRACT RESEARCH ORGANIZATIONS FOR ONCOLOGY DIAGNOSTICS
TABLE 49 TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
9.6 OTHER END USERS
TABLE 50 TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
10 TISSUE DIAGNOSTICS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 51 TISSUE DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 30 TISSUE DIAGNOSTICS MARKET: NORTH AMERICA SNAPSHOT
TABLE 52 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 54 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 55 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 56 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
TABLE 57 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 58 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.1 US
10.2.1.1 High healthcare expenditure to drive market
TABLE 59 US CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
TABLE 60 US: KEY MACROINDICATORS
TABLE 61 LIST OF US FDA-APPROVED PRODUCTS FOR TISSUE DIAGNOSTICS
TABLE 62 US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 63 US: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 64 US: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 65 US: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 66 US: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.2 CANADA
10.2.2.1 High prevalence of cancer to support market growth
TABLE 67 CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
TABLE 68 CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 69 CANADA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 70 CANADA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 71 CANADA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 72 CANADA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 NORTH AMERICA: RECESSION IMPACT
10.3 EUROPE
TABLE 73 EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 74 EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 75 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 76 EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 77 EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
TABLE 78 EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 79 EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Availability of reimbursements for colorectal cancer screening procedures to support market growth
TABLE 80 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 81 GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 82 GERMANY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 83 GERMANY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 84 GERMANY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 85 GERMANY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION
10.3.2 UK
10.3.2.1 Rising investments in cancer research to propel market
TABLE 86 UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 87 UK: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 88 UK: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 89 UK: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 90 UK: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Growing focus on early disease diagnosis to boost demand
TABLE 91 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 92 FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 93 FRANCE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 94 FRANCE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 95 FRANCE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 96 FRANCE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 ITALY
10.3.4.1 High incidence of cancer and geriatric population to support market growth
TABLE 97 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 98 ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 99 ITALY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 100 ITALY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 101 ITALY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 102 ITALY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 High incidence of chronic diseases to drive market
TABLE 103 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
TABLE 104 SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 105 SPAIN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 106 SPAIN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 107 SPAIN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 108 SPAIN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 109 REST OF EUROPE: CANCER INCIDENCE, 2020 VS. 2025
TABLE 110 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 111 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 112 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 113 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 114 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 EUROPE: RECESSION IMPACT
10.4 ASIA PACIFIC
FIGURE 31 TISSUE DIAGNOSTICS MARKET: ASIA PACIFIC SNAPSHOT
TABLE 115 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 116 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 117 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 118 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 119 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2021–2028 (USD MILLION)
TABLE 120 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 121 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Rising incidence of chronic & infectious diseases to propel market
TABLE 122 CANCER INCIDENCE, BY CANCER TYPE (CHINA), 2020 VS. 2025
TABLE 123 CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 124 CHINA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 CHINA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 126 CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 127 CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Development of advanced diagnostic products to fuel market
TABLE 128 CANCER INCIDENCE, BY CANCER TYPE (JAPAN), 2020 VS. 2040
TABLE 129 JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 130 JAPAN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 131 JAPAN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 132 JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 133 JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Rising establishment of diagnostic centers to drive market
TABLE 134 INDIA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
TABLE 135 INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 136 INDIA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 INDIA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 138 INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 139 INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 140 REST OF ASIA PACIFIC: CANCER INCIDENCE, 2020 VS. 2040
TABLE 141 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 142 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 143 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 144 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 145 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 ASIA PACIFIC: RECESSION IMPACT
10.5 REST OF THE WORLD
TABLE 146 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 147 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 148 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 149 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 150 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
TABLE 151 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 152 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.1 LATIN AMERICA
10.5.1.1 Rising number of cancer screening programs to drive market
TABLE 153 LATIN AMERICA: CANCER INCIDENCE, 2020 VS. 2025
TABLE 154 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 155 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 156 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 157 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 158 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.2 MIDDLE EAST & AFRICA
10.5.2.1 Improvements in healthcare infrastructure to support market growth
TABLE 159 CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2025
TABLE 160 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 161 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 162 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 163 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 164 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.3 REST OF THE WORLD: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY MARKET PLAYERS
TABLE 165 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET
11.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET
11.4 MARKET SHARE ANALYSIS
TABLE 166 TISSUE DIAGNOSTICS MARKET: INTENSITY OF COMPETITIVE RIVALRY
FIGURE 33 TISSUE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)
11.5 COMPANY EVALUATION MATRIX
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 34 TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
11.5.5 COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 167 COMPANY FOOTPRINT
11.5.6 PRODUCT FOOTPRINT
11.5.7 REGIONAL FOOTPRINT
11.6 START-UP/SME EVALUATION MATRIX
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 35 TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES
11.7 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
TABLE 168 TISSUE DIAGNOSTICS MARKET: KEY STARTUPS/SMES
11.8 COMPETITIVE SCENARIOS AND TRENDS
11.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 169 TISSUE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020?OCTOBER 2023)
11.8.2 DEALS
TABLE 170 TISSUE DIAGNOSTICS MARKET: DEALS (JANUARY 2020?OCTOBER 2023)
11.8.3 OTHER DEVELOPMENTS
TABLE 171 TISSUE DIAGNOSTIC MARKET: OTHER DEVELOPMENTS (JANUARY 2020?OCTOBER 2023)
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
12.1 KEY PLAYERS
12.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 172 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
12.1.2 DANAHER CORPORATION
TABLE 173 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
12.1.3 PHC HOLDINGS CORPORATION
TABLE 174 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 38 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
12.1.4 THERMO FISHER SCIENTIFIC INC.
TABLE 175 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 39 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
12.1.5 ABBOTT
TABLE 176 ABBOTT: BUSINESS OVERVIEW
FIGURE 40 ABBOTT: COMPANY SNAPSHOT (2022)
12.1.6 AGILENT TECHNOLOGIES, INC.
TABLE 177 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 41 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2022)
12.1.7 MERCK KGAA
TABLE 178 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2022)
12.1.8 SAKURA FINETEK JAPAN CO., LTD.
TABLE 179 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW
12.1.9 ABCAM PLC
TABLE 180 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 43 ABCAM PLC. COMPANY SNAPSHOT (2022)
12.1.10 BECTON, DICKINSON AND COMPANY (BD)
TABLE 181 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 44 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
12.1.11 BIO SB
TABLE 182 BIO SB: BUSINESS OVERVIEW
12.1.12 BIOGENEX
TABLE 183 BIOGENEX: BUSINESS OVERVIEW
12.1.13 CELL SIGNALING TECHNOLOGY, INC.
TABLE 184 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
12.1.14 HISTO-LINE LABORATORIES
TABLE 185 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW
12.1.15 SLEE MEDICAL GMBH
TABLE 186 SLEE MEDICAL GMBH: BUSINESS OVERVIEW
12.1.16 CELLPATH LTD.
TABLE 187 CELLPATH LTD.: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 AMOS SCIENTIFIC PTY LTD.
12.2.2 JINHUA YIDI MEDICAL APPLIANCE CO., LTD.
12.2.3 MEDITE MEDICAL GMBH
12.2.4 DIAPATH S.P.A.
12.2.5 KFBIO KONFOONG BIOINFORMATION TECH CO., LTD
12.2.6 DIAGNOSTIC BIOSYSTEMS INC.
12.2.7 3DHISTECH LTD.
12.2.8 RWD LIFE SCIENCE CO., LTD.
12.2.9 DAKEWE
12.2.10 SYSMEX CORPORATION
12.2.11 ENZO LIFE SCIENCES, INC.
12.2.12 BIOCARE MEDICAL, LLC.
12.2.13 MILESTONE MEDICAL
12.2.14 BIO-OPTICA MILANO SPA
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS COVERED
FIGURE 1 MARKET SEGMENTATION
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 5 REVENUE SHARE ANALYSIS
FIGURE 6 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
FIGURE 7 TISSUE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.5.1 MARKET ASSUMPTIONS
2.5.2 GROWTH RATE ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT ANALYSIS
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 9 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
FIGURE 10 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
FIGURE 11 TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD BILLION)
FIGURE 12 TISSUE DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF TISSUE DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 TISSUE DIAGNOSTICS MARKET OVERVIEW
FIGURE 14 RISING INCIDENCE OF CANCER AND INFECTIOUS DISEASES TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
4.2 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2022)
FIGURE 15 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
4.3 TISSUE DIAGNOSTICS MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 16 CHINA & INDIA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 TISSUE DIAGNOSTICS MARKET: REGIONAL MIX
FIGURE 17 ASIA PACIFIC REGION IS PROJECTED TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
4.5 TISSUE DIAGNOSTICS MARKET: DEVELOPED COUNTRIES VS. EMERGING ECONOMIES
FIGURE 18 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of cancer and infectious diseases
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2018 VS. 2020 VS. 2040
5.2.1.2 Growing demand for digital pathology
5.2.1.3 Increasing healthcare expenditure
FIGURE 20 CURRENT HEALTH EXPENDITURE PER CAPITA
FIGURE 21 CURRENT HEALTH EXPENDITURE (% OF GDP)
5.2.1.4 Growing availability of reimbursements
5.2.1.5 Rising establishment of private diagnostics centers
5.2.2 RESTRAINTS
5.2.2.1 High cost of tissue diagnostic systems
5.2.2.2 Stringent regulatory requirements
5.2.3 OPPORTUNITIES
5.2.3.1 High growth potential of emerging economies
FIGURE 22 GROWTH IN CURRENT HEALTHCARE EXPENDITURE IN BRICS COUNTRIES, 2012–2020
5.2.3.2 Growing preference for personalized medicines
FIGURE 23 PERSONALIZED MEDICINES APPROVED BY FDA (%), 2015–2022
5.2.3.3 Increasing number of clinical trials for cancer therapeutics
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled professionals
5.2.4.2 Availability of refurbished products
5.2.4.3 Inadequate standardization for TDx
5.2.5 INDUSTRY TRENDS
5.2.5.1 Increasing number of reagent rental agreements
5.2.5.2 Growing usage of AI in histopathology
5.3 VALUE CHAIN ANALYSIS
FIGURE 24 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 25 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.5 TECHNOLOGY ANALYSIS
5.6 PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 BARGAINING POWER OF BUYERS
5.6.3 BARGAINING POWER OF SUPPLIERS
5.6.4 THREAT OF SUBSTITUTES
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 KEY STAKEHOLDERS AND BUYING CRITERIA
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USERS
TABLE 4 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)
5.7.2 BUYING CRITERIA
FIGURE 27 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 5 KEY BUYING CRITERIA FOR END USERS
5.8 REGULATORY LANDSCAPE
TABLE 6 INDICATIVE LIST OF REGULATORY AUTHORITIES IN TISSUE DIAGNOSTICS MARKET
5.9 PATENT ANALYSIS
5.10 KEY CONFERENCES AND EVENTS
TABLE 7 LIST OF CONFERENCES & EVENTS (2023?2024)
5.11 PRICING ANALYSIS
TABLE 8 PRICE RANGE FOR TISSUE DIAGNOSTICS
5.12 TRADE ANALYSIS
TABLE 9 IMPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL/CHEMICAL ANALYSIS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 10 EXPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL/CHEMICAL ANALYSIS, BY COUNTRY, 2018–2022 (USD MILLION)
5.13 ECOSYSTEM MARKET/MAP
TABLE 11 TISSUE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
FIGURE 28 KEY PLAYERS OPERATING IN TISSUE DIAGNOSTICS MARKET
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6 TISSUE DIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 12 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 CONSUMABLES
TABLE 13 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 14 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2021–2028 (USD MILLION)
6.2.1 ANTIBODIES
6.2.1.1 Rising prevalence of infectious diseases to drive market
TABLE 15 TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
6.2.2 KITS
6.2.2.1 Optimized sensitivity and versatility to boost demand
TABLE 16 TISSUE DIAGNOSTICS MARKET FOR KITS, BY REGION, 2021–2028 (USD MILLION)
6.2.3 REAGENTS
6.2.3.1 Rising uptake in IHC and FISH procedures to support market growth
TABLE 17 TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2021–2028 (USD MILLION)
6.2.4 PROBES
6.2.4.1 Utilization in fluorescence microscopy applications to boost demand
TABLE 18 TISSUE DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS
TABLE 19 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 20 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
6.3.1 SLIDE-STAINING SYSTEMS
6.3.1.1 Development of high-throughput staining systems to drive market
TABLE 21 KEY MANUFACTURERS OF AUTOMATED SLIDE STAINERS
TABLE 22 TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2021–2028 (USD MILLION)
6.3.2 SCANNERS
6.3.2.1 Rising use of multiplexed IHC scanners to drive market
TABLE 23 TISSUE DIAGNOSTICS MARKET FOR SCANNERS, BY REGION, 2021–2028 (USD MILLION)
6.3.3 TISSUE-PROCESSING SYSTEMS
6.3.3.1 Rising need for automation to support market growth
TABLE 24 TISSUE DIAGNOSTICS MARKET FOR TISSUE-PROCESSING SYSTEMS, BY REGION, 2021–2028 (USD MILLION)
6.3.4 OTHER INSTRUMENTS
TABLE 25 TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
7 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 26 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 IMMUNOHISTOCHEMISTRY
7.2.1 RISING UPTAKE OF IHC KITS FOR DIAGNOSTIC APPLICATIONS TO FUEL MARKET
TABLE 27 TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2021–2028 (USD MILLION)
7.3 IN SITU HYBRIDIZATION
7.3.1 ABILITY TO DETECT SPECIFIC RNA AND DNA SEQUENCES TO BOOST DEMAND
TABLE 28 TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2021–2028 (USD MILLION)
7.4 DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT
7.4.1 RISING NEED FOR ANALYSIS AND SEAMLESS MANAGEMENT TO SUPPORT MARKET GROWTH
TABLE 29 TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT, BY REGION, 2021–2028 (USD MILLION)
7.5 SPECIAL STAINING
7.5.1 UTILIZATION IN CANCER DIAGNOSTICS TO BOOST DEMAND
TABLE 30 TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION, 2021–2028 (USD MILLION)
8 TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE
8.1 INTRODUCTION
TABLE 31 GLOBAL CANCER INCIDENCE, 2020 VS. 2040
TABLE 32 TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
8.2 BREAST CANCER
8.2.1 RISING UPTAKE OF HER2 TESTS FOR CANCER DIAGNOSIS TO DRIVE MARKET
TABLE 33 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
FIGURE 29 ARTICLES PUBLISHED ON BREAST CANCER TISSUE DIAGNOSTICS, 2011–2021
TABLE 34 TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION)
8.3 GASTRIC CANCER
8.3.1 RISING INCIDENCE OF GASTROINTESTINAL CANCER TO BOOST DEMAND
TABLE 35 COLON CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 36 TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2021–2028 (USD MILLION)
8.4 LYMPHOMA
8.4.1 RISING INCIDENCE OF NON-HODGKIN’S LYMPHOMA IN ADULTS TO SUPPORT MARKET GROWTH
TABLE 37 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 38 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 39 TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION, 2021–2028 (USD MILLION)
8.5 PROSTATE CANCER
8.5.1 RISING UPTAKE OF ISH TESTS FOR DIAGNOSIS TO FUEL MARKET
TABLE 40 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040
TABLE 41 TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION)
8.6 NON-SMALL CELL LUNG CANCER
8.6.1 GROWING FOCUS ON DEVELOPING COMPANION DIAGNOSTIC TESTS TO DRIVE MARKET
TABLE 42 TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2021–2028 (USD MILLION)
8.7 OTHER DISEASE TYPES
TABLE 43 TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASE TYPES, BY REGION, 2021–2028 (USD MILLION)
9 TISSUE DIAGNOSTICS MARKET, BY END USER
9.1 INTRODUCTION
TABLE 44 TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 HOSPITALS
9.2.1 ABILITY TO OFFER ADVANCED EQUIPMENT & INFRASTRUCTURE TO DRIVE MARKET
TABLE 45 TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
9.3 RESEARCH LABORATORIES
9.3.1 RISING DEMAND OF SPECIALTY TESTS TO DRIVE MARKET
TABLE 46 TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
9.4 PHARMACEUTICAL COMPANIES
9.4.1 INCREASING R&D ACTIVITIES FOR DISEASE DIAGNOSTICS TO DRIVE MARKET
TABLE 47 TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 OUTSOURCING OF R&D ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 48 CONTRACT RESEARCH ORGANIZATIONS FOR ONCOLOGY DIAGNOSTICS
TABLE 49 TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
9.6 OTHER END USERS
TABLE 50 TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
10 TISSUE DIAGNOSTICS MARKET, BY REGION
10.1 INTRODUCTION
TABLE 51 TISSUE DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 30 TISSUE DIAGNOSTICS MARKET: NORTH AMERICA SNAPSHOT
TABLE 52 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 54 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 55 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 56 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
TABLE 57 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 58 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.1 US
10.2.1.1 High healthcare expenditure to drive market
TABLE 59 US CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
TABLE 60 US: KEY MACROINDICATORS
TABLE 61 LIST OF US FDA-APPROVED PRODUCTS FOR TISSUE DIAGNOSTICS
TABLE 62 US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 63 US: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 64 US: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 65 US: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 66 US: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.2 CANADA
10.2.2.1 High prevalence of cancer to support market growth
TABLE 67 CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
TABLE 68 CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 69 CANADA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 70 CANADA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 71 CANADA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 72 CANADA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2.3 NORTH AMERICA: RECESSION IMPACT
10.3 EUROPE
TABLE 73 EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 74 EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 75 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 76 EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 77 EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
TABLE 78 EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 79 EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Availability of reimbursements for colorectal cancer screening procedures to support market growth
TABLE 80 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 81 GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 82 GERMANY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 83 GERMANY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 84 GERMANY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 85 GERMANY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION
10.3.2 UK
10.3.2.1 Rising investments in cancer research to propel market
TABLE 86 UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 87 UK: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 88 UK: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 89 UK: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 90 UK: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Growing focus on early disease diagnosis to boost demand
TABLE 91 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 92 FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 93 FRANCE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 94 FRANCE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 95 FRANCE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 96 FRANCE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.4 ITALY
10.3.4.1 High incidence of cancer and geriatric population to support market growth
TABLE 97 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 98 ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 99 ITALY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 100 ITALY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 101 ITALY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 102 ITALY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 High incidence of chronic diseases to drive market
TABLE 103 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
TABLE 104 SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 105 SPAIN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 106 SPAIN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 107 SPAIN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 108 SPAIN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 109 REST OF EUROPE: CANCER INCIDENCE, 2020 VS. 2025
TABLE 110 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 111 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 112 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 113 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 114 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.3.7 EUROPE: RECESSION IMPACT
10.4 ASIA PACIFIC
FIGURE 31 TISSUE DIAGNOSTICS MARKET: ASIA PACIFIC SNAPSHOT
TABLE 115 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 116 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 117 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 118 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 119 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2021–2028 (USD MILLION)
TABLE 120 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 121 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Rising incidence of chronic & infectious diseases to propel market
TABLE 122 CANCER INCIDENCE, BY CANCER TYPE (CHINA), 2020 VS. 2025
TABLE 123 CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 124 CHINA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 CHINA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 126 CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 127 CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Development of advanced diagnostic products to fuel market
TABLE 128 CANCER INCIDENCE, BY CANCER TYPE (JAPAN), 2020 VS. 2040
TABLE 129 JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 130 JAPAN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 131 JAPAN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 132 JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 133 JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Rising establishment of diagnostic centers to drive market
TABLE 134 INDIA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
TABLE 135 INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 136 INDIA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 INDIA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 138 INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 139 INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 140 REST OF ASIA PACIFIC: CANCER INCIDENCE, 2020 VS. 2040
TABLE 141 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 142 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 143 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 144 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 145 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.4.5 ASIA PACIFIC: RECESSION IMPACT
10.5 REST OF THE WORLD
TABLE 146 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 147 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 148 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 149 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 150 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
TABLE 151 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 152 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.1 LATIN AMERICA
10.5.1.1 Rising number of cancer screening programs to drive market
TABLE 153 LATIN AMERICA: CANCER INCIDENCE, 2020 VS. 2025
TABLE 154 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 155 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 156 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 157 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 158 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.2 MIDDLE EAST & AFRICA
10.5.2.1 Improvements in healthcare infrastructure to support market growth
TABLE 159 CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2025
TABLE 160 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 161 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION)
TABLE 162 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 163 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 164 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.5.3 REST OF THE WORLD: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY MARKET PLAYERS
TABLE 165 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET
11.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET
11.4 MARKET SHARE ANALYSIS
TABLE 166 TISSUE DIAGNOSTICS MARKET: INTENSITY OF COMPETITIVE RIVALRY
FIGURE 33 TISSUE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2022)
11.5 COMPANY EVALUATION MATRIX
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 34 TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
11.5.5 COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 167 COMPANY FOOTPRINT
11.5.6 PRODUCT FOOTPRINT
11.5.7 REGIONAL FOOTPRINT
11.6 START-UP/SME EVALUATION MATRIX
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 35 TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES
11.7 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
TABLE 168 TISSUE DIAGNOSTICS MARKET: KEY STARTUPS/SMES
11.8 COMPETITIVE SCENARIOS AND TRENDS
11.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 169 TISSUE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020?OCTOBER 2023)
11.8.2 DEALS
TABLE 170 TISSUE DIAGNOSTICS MARKET: DEALS (JANUARY 2020?OCTOBER 2023)
11.8.3 OTHER DEVELOPMENTS
TABLE 171 TISSUE DIAGNOSTIC MARKET: OTHER DEVELOPMENTS (JANUARY 2020?OCTOBER 2023)
12 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
12.1 KEY PLAYERS
12.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 172 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
12.1.2 DANAHER CORPORATION
TABLE 173 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
12.1.3 PHC HOLDINGS CORPORATION
TABLE 174 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 38 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
12.1.4 THERMO FISHER SCIENTIFIC INC.
TABLE 175 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 39 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
12.1.5 ABBOTT
TABLE 176 ABBOTT: BUSINESS OVERVIEW
FIGURE 40 ABBOTT: COMPANY SNAPSHOT (2022)
12.1.6 AGILENT TECHNOLOGIES, INC.
TABLE 177 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 41 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2022)
12.1.7 MERCK KGAA
TABLE 178 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2022)
12.1.8 SAKURA FINETEK JAPAN CO., LTD.
TABLE 179 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW
12.1.9 ABCAM PLC
TABLE 180 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 43 ABCAM PLC. COMPANY SNAPSHOT (2022)
12.1.10 BECTON, DICKINSON AND COMPANY (BD)
TABLE 181 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 44 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
12.1.11 BIO SB
TABLE 182 BIO SB: BUSINESS OVERVIEW
12.1.12 BIOGENEX
TABLE 183 BIOGENEX: BUSINESS OVERVIEW
12.1.13 CELL SIGNALING TECHNOLOGY, INC.
TABLE 184 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
12.1.14 HISTO-LINE LABORATORIES
TABLE 185 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW
12.1.15 SLEE MEDICAL GMBH
TABLE 186 SLEE MEDICAL GMBH: BUSINESS OVERVIEW
12.1.16 CELLPATH LTD.
TABLE 187 CELLPATH LTD.: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 AMOS SCIENTIFIC PTY LTD.
12.2.2 JINHUA YIDI MEDICAL APPLIANCE CO., LTD.
12.2.3 MEDITE MEDICAL GMBH
12.2.4 DIAPATH S.P.A.
12.2.5 KFBIO KONFOONG BIOINFORMATION TECH CO., LTD
12.2.6 DIAGNOSTIC BIOSYSTEMS INC.
12.2.7 3DHISTECH LTD.
12.2.8 RWD LIFE SCIENCE CO., LTD.
12.2.9 DAKEWE
12.2.10 SYSMEX CORPORATION
12.2.11 ENZO LIFE SCIENCES, INC.
12.2.12 BIOCARE MEDICAL, LLC.
12.2.13 MILESTONE MEDICAL
12.2.14 BIO-OPTICA MILANO SPA
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
